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Abstract
Background It is debated whether iso-osmolar and low-
osmolar contrast media are associated with different
incidences of contrast medium-induced nephropathy (CIN)
in patients with renal insufficiency.
Objective To compare the incidence of CIN in children
undergoing contrast-enhanced multidetector computer to-
mography (MDCT) with intravenous injection of low-
osmolar (iobitridol, Xenetix® 300) or an iso-osmolar
(iodixanol, Visipaque® 270) iodinated contrast medium.
Materials and methods One hundred forty-six children
with normal renal function were included in this multicenter
trial and underwent contrast-enhanced MDCT. The primary
endpoint was the relative change in creatinine clearance
from 48 h pre- to 72 h postcontrast medium administration
using a noninferiority analysis in the intent-to-treat (ITT,
n=128) and per protocol (n=68) populations. Secondary
endpoints were incidence of CIN, global image quality,
diagnostic efficacy and clinical safety.
Results In the ITT population, the noninferiority of
iobitridol over iodixanol was demonstrated. CIN incidence
was 4.8% (three cases) with iobitridol and 10.6% (seven
cases) with iodixanol (not significant). No statistically
significant differences were observed for the secondary
endpoints.
Conclusion Comparable satisfactory safety profiles were
confirmed for both contrast media, with no significant
difference in the incidence of CIN in children with normal
renal function.
Keywords Contrast medium-induced nephropathy.
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Introduction
The use of iodinated contrast media (CM) has increased
over the past decades and is a well-known cause of acute
renal failure, especially in patients with impaired renal
function and/or in those with diabetes mellitus [1–3].
Iodinated contrast medium-induced nephropathy (CIN) is
a potentially serious complication of diagnostic or interven-
tional procedures leading to dialysis, prolonged hospitali-
zation, increased morbidity and mortality [4].
Iodinated CM are either ionic or nonionic and vary in
their osmolality relative to plasma. It is now widely
acknowledged that high-osmolality CM (ionic) are more
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ionic or nonionic, in at-risk patients [5]. However, whether
there are differences in safety among the various CM,
particularly with regard to nephrotoxicity, remains contro-
versial. Many clinical studies and meta-analyses have
compared the safety of the various CM; however, depending
on the patient population and study design, results are
controversial [6–13].
CIN is generally characterised by an increase in serum
creatinine of more than 25% or 0.5 mg/dl (44 μmol/l)
over baseline, occurring within 3 days of CM adminis-
tration. Serum creatinine is a relatively crude measure of
glomerular filtration rate, and it has been suggested that
creatinine clearance should be used to identify at-risk
patients, as it provides better indication of renal function
[14, 15].
The incidence of CIN is low (around 5%) in patients
without risk factors, but is increased (up to 50%) in patients
with multiple risk factors [16]. These risk factors include
contrast dose, contrast osmolality, previous CM injection
and route of administration of CM [17]. The risk of CIN is
estimated to be more than twofold lower when administered
intravenously rather than intra-arterially [14, 18].
Few clinical studies have compared the renal effects of
intravenous administration of a low osmolar and an iso-
osmolar contrast agent. There are very few studies of the
effects in children in particular [19, 20].
Whether the use of an isotonic contrast agent confers any
additional benefit in children compared with a low-osmolar
agent is unclear. Therefore, the purpose of this randomized
phase IV multicenter study was to compare the incidence of
CIN in children undergoing enhanced multidetector com-
puter tomography (MDCT) after intravenous administration
of a low-osmolar (iobitridol) or an iso-osmolar (iodixanol)
contrast agent.
Materials and methods
Study conduct and patient enrollment conditions
The study was approved by the Institutional Review Board
of each participating center and performed according to
good clinical practice standards. Informed written consent
was obtained from each patient and/or patient’s parents
before any study-specific procedures were performed.
Children between 1 and 16 years of age with normal
renal function (creatinine clearance >60 ml/min/1.73 m
2,
calculated by the Schwartz’s formula [21]), scheduled to
undergo a clinically indicated contrast-enhanced MDCT
examination were considered eligible for inclusion. Patients
were excluded from the trial in case of pregnancy or known
hypersensitivity to iodine-containing compounds. Patients
were also excluded if they had received any iodinated
contrast agent within 7 days before the administration of the
investigational product, if they were scheduled to receive an
iodinated contrast agent within 72 h after administration of
the investigational product, if they received any nephrotoxic
medication (chemotherapeutic agents, diuretics or biguanide),
or if they had any surgery planned within 72 h after the
administration of the contrast agent.
After obtaining written informed consent and verifying
all selection criteria, patients included in the study were
then allocated an identification number corresponding to
their chronological rank of inclusion. Patients were
assigned randomly to intravenous administration of the
LOCM iobitridol (695 mOsm/kg H2O) or the IOCM
iodixanol (290 mOsm/kg H2O). LOCM are defined as
CM with an osmolality two to three times that of normal
human blood at an iodine concentration around 300 mg/ml.
IOCM are defined as CM that are iso-osmolar to blood at
an iodine concentration around 320 mg/ml. All groups and
individuals associated with the study remained blinded to
the type of contrast medium until the database was locked
and the data analyzed. The randomization list was stratified
by center. The MDCT images were assessed subjectively
on-site by one experienced reader at each participating site.
If needed, patients between 1 and 6 years received
hydroxyzine for sedation (2 mg/kg body weight). Pre-
procedure hydration was not implemented in this study.
Contrast medium administration
To ensure blinding at the investigational sites, a third-party
operator dispensed the drugs, managed the preparation,
dispensation and accountability of the investigational
agents, as per code assignment. The sole responsibility of
all operators who dispensed the drugs was to preserve the
blinding, and therefore they did not participate in any of the
study assessments.
Contrast medium (iobitridol, Xenetix® 300, Guerbet
Laboratories, Roissy, France or iodixanol, Visipaque® 270,
GE Healthcare SA) was administered by intravenous
injection according to a total volume depending on the
patient’s weight. All scans were performed following
administration of 2 ml/kg body weight, maximum 100 ml,
of contrast medium. The first part of the study applied a
maximum volume of 50 ml.
Evaluation of primary and secondary endpoints
The primary endpoint was the relative change [22]i n
creatinine clearance from 48 h before to 72 h after contrast
medium administration using a noninferiority analysis.
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(defined as more than 25% reduction in creatinine clear-
ance), global image quality on a 3-point scale (poor: low
and inhomogeneous enhancement of target structures,
moderate: little, but still homogeneous enhancement of
target structures, good: adequate, almost completely homo-
geneous signal enhancement of target structures) and
diagnosis efficacy on a 3-point scale (impossible: not
providing enough information, difficult: not providing all
the expected information, easy: providing the expected
information). Moreover, the safety profile (vital signs and
adverse events) of both contrast agents was also recorded.
Any event from inclusion until the end of the 10-day
follow-up period was collected and reported.
We evaluated the causality between the investigational
product and /or concomitant therapy and the adverse event.
The imputability of any reactions to the contrast agent was
excluded if no causal relationship existed between the study
drug and the event and an obvious alternative cause existed
(e.g., the patient’s underlying medical condition or con-
comitant therapy).
Statistical analysis
Assuming that the relative variation of the creatinine
clearance from baseline is around 0.10 (10%) on average
for both contrast agents with a 0.10 standard deviation, a
sample of 128 patients was considered sufficient for 80%
power and 2.5% type-1 error to ensure that if the difference
between both products would not exceed −0.05 in disfavor
of iobitridol, the noninferiority of iobitridol would be
demonstrated over iodixanol. Assuming a 10% dropout,
the sample size was extended to 142 patients to reach the
main study objective.
Creatinine clearance was calculated in both groups before
and after injection of contrast agents and the relative variation
ofthesemeasureswascomputedandcomparedineachgroup.
The noninferiority analysis on the primary endpoint was
tested using the noncentral Student’s t-test with a 2-sided
type-1 error set at 0.05. The noninferiority of iobitridol over
iodixanol was established if the observed difference between
groups differed from the noninferiority clinical limit set at
−0.05 in the study. This margin was considered by the study
investigators as clinically sufficiently low to conclude a non-
difference between the contrast agents.
Descriptive statistics were used for demography and
baseline characteristics. The statistical test used for analyzing
CIN incidence, image quality and diagnostic efficacy was the
Wald Chi-2testusing a generalized linear model.The P-value
for the main effect (difference between products) was
adjusted on centers, mainly to take into account the
stratification of the randomization by centre.
Statistical analyses were conducted using the software
SAS version 9.1 (SAS Institute, Cary, N.C.).
The intent-to-treat (ITT) population refers to patients
receiving at least one injection of contrast agent, and
presenting with a valid creatinine clearance variation. The
findings in this population were used for the primary and
secondary criteria analyses. The per protocol (PP) popula-
tion includes patients where there was no protocol deviation
or violation. This population was also included in the
primary and secondary criteria analyses. The safety popu-
lation included all patients who received at least one dose
of the study product and was used for the safety analyses.
Results
Patients
Between May 2006 and March 2009, 146 children with
normal kidney function scheduled to undergo clinically
indicated MDCTwere recruited. One patient did not receive
the product, hence, 145 children were randomized to
receive iobitridol 300 (n=74) or iodixanol (n=71), and
were all eligible for the safety analysis.
As shown in Table 1, the two treatment groups were
well-balanced with regard to demographic and baseline
data. None of the patients had renal insufficiency. The most
common indication was the “others” category, with the
largest sub categories being liver transplant assessment,
headache and Crohn disease.
Among the 146 children enrolled in the study, 18 were
excluded from the ITT analysis, making 128 children
eligible for the ITT population. The main reason for
excluding children from ITT analysis was missing creati-
nine measurement.
From the ITT population, 68 children were free of major
protocol deviations and were therefore eligible for the per-
protocol analysis. The main reasons for excluding children
from PP analysis were creatinine measurement out of time
frame (48 h before injection or 72±24 h after injection),
contrast medium dose out of range (2 ml/kg ±10%) and
code breaking.
Primary endpoint
In the ITT population (n=128), the mean difference
(iobitridol−iodixanol) in creatinine clearance variation from
baseline was −0.12% (P=0.042), which was significantly
different from the noninferiority margin (−0.05), demonstrat-
ing the noninferiority of iobitridol over iodixanol. The results
were consistent in the per-protocol population (68 children),
with a mean difference of 2.2% (P=0.027; Table 2).
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CIN incidence
CIN was observed in 3/62 patients (4.8%) with iobitridol
and 7/66 patients (10.6%) with iodixanol, with no statisti-
cally significant difference between groups in the ITT
population (P=0.72). Similar results were found in the PP
population (P=0.68) (Table 3). Characteristics of these
patients are detailed in Table 4.
Image quality assessment
The image quality rated “good” was similar in both
groups: 52/62 patients (83.9%) with iobitridol 300 versus
59/66 patients (89.4%) with iodixanol 270, with no
Table 2 Increase in creatinine clearance at day 3 following contrast medium administration compared to baseline. ITT Intent-to-treat population,
PP per protocol population
Creatinine clearance
(ml min
−1 1.73 m
−2)
Iobitridol 300 Iodixanol 270 Difference (iobitridol-iodixanol)
(90% confidence interval) P
ITT n=62 n=66 −0.12% (−0.0481; 0.0456) P=0.042
Mean (%±SD) 0.011 ±0.197 0.019 ±0.220
Min/max −0.387/0.953 −0.584/0.769
PP n=29 n=39 2.2% (−0.0405; 0.0844) P=0.027
Mean (%±SD) 0.039 ±0.222 0.018 ±0.200
Min/max −0.237/0.953 −0.320/0.693
Table 1 Demographic and baseline characteristics, indications for multidetector computer tomography (MDCT) and patient condition. BMI Body
mass index
Iobitridol 300 (n=74) Iodixanol 270 (n=71) Total (n=145)
Baseline characteristics
Age (years) mean ±SD, (min–max) 8.7 ±4.8 (1.0–16.0) 8.1 ±4.7 (0.0–16.0) 8.4 ±4.7 (0.0–16.0)
Male 43 ( 58.1 % ) 43 (60.6 %) 86 (59.3 %)
Female 31 ( 41.9 % ) 28 (39.4 % ) 59 (40.7%)
BMI (kg m
−2) mean ±SD, (min–max) 17.7 ±3.7 (12.7–33.6) 17.4 ±3.2 (11.8–25.7) 17.6 ±3.4 (11.8–33.6)
Baseline serum creatinine (μmol/l) mean ±SD,
(min–max)
46.4 ±15.8 (17.9–84.0) 43.6 ±17.1 (15.0–89.0) 45.0 ±16.5 (15.0–89.0)
Baseline creatinine clearance (ml min
−1 1.73 m
−2)
mean ±SD, (min–max)
154.7 ±44.3 (70.8–315.6) 157.9 ±44.4 (73.5–260.7) 156.4 ±44.2 (70.8–315.6)
Indications for MDCT examination (N, %)
Congenital malformation
Cardiac 15 (20.3%) 11 (15.5%) 26 (17.9%)
Vascular 5 (6.8 %) 4 (5.6 %) 9 (6.2 %)
Others 3 (4.1 %) 5 (7.0 %) 8 (5.5 %)
Tumors
Abdomino-pelvic 1 (1.4%) 5 (7.0%) 6 (4.1%)
Cerebral 1 (1.4 %) 3 (4.2%) 4 (2.8 %)
Others 6 (8.1 %) 3 (4.2%) 9 (6.2 %)
Trauma 6 (8.1%) 4 (5.2 %) 10 (6.9%)
Other
a 41 (55.4%) 42 (59.2%) 83 (57.2%)
Patient disposition
Total number of randomized patients 74 71 145
Safety population 74 (100%) 71 (100%) 145 (100%)
Intent-to-treat population 62 (83.8% ) 66 (93.0%) 128 (88.3%)
Per protocol population 29 (39.2%) 39 (54.9%) 68 (46.9%)
aMainly liver transplantation, headache and Crohn disease
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0.73) (Table 5).
Image quality was judged as “poor” or “moderate” in
patients with high BMI, in those who did not receive a
sufficient dose, and in the one case with extravasation, in
the iobitridol group, when contrast administration had to be
suspended.
Diagnostic efficacy
The diagnostic efficacy rated “easy” was similar in both
groups: 56/62 patients (90.3%) with iobitridol 300 versus 65/
66 patients (98.5%) with iodixanol 270, with no statistically
significant difference between groups (P=0.58) (Table 5).
When the diagnostic efficacy was assessed as impossible
or difficult, this was related mainly to patients with poor or
moderate image quality.
General safety
The mean volume of contrast agent injected was 54.2 ml (10–
100 ml). The mean amount of iodine administered was
slightly higher in the iobitridol 300 group [16.3 ±7.3 g (3.0–
30.0)] compared to the iodixanol 270 group [14.6 ±7.0 g
(3.24–27.0)].
All patients were followed for 10 days after MDCT. A
total of 16/74 patients (21.6%) with iobitridol 300 and 17/
71 patients (23.9%) with iodixanol 270 experienced at least
one adverse event. A total of 43 adverse events were
observed: 20 (46.5%) with iobitridol 300 (including two
pre-injection adverse events) and 23 (53.4%) with iodixanol
270. Most of these were of mild/moderate intensity.
Relationship to the products was assumed for 9 (45%)
adverse events (1 case of pruritis, 3 cases of rash, 1 case of
extravasation and 4 cases of increased creatinine) with
iobitridol 300 and 12 (52.1%) adverse events (1 case each
of dermatitis, injection site warmth, pyrexia, rash and
nausea, 5 cases of increased blood creatinine and 2 cases
of vomiting) with iodixanol 270.
A total of nine serious adverse events were reported, five
following iobitridol 300 and four following iodixanol 270.
None of these was considered related to the products.
Discussion
This double-blind, randomized, controlled study performed
in children with normal renal function showed that
iobitridol 300 was noninferior to iodixanol 270 in terms
of relative variation of the creatinine clearance despite a
higher iodine load in the iobitridol group.
Many studies have demonstrated that high-osmolar
contrast media are more nephrotoxic than new generation,
low and iso-osmolar alternatives [3, 23, 24], as also noted
in the guidelines from the European Society of Urogenital
Table 3 Incidence of contrast medium-induced nephropathy (CIN)
(creatinine clearance reduced >25% compared to baseline)
Iobitridol 300 Iodixanol 270 P
a
ITT n=62 n=66 0.72
3 (4.8%) 7 (10.6%)
PP n=29 n=39 0.68
0 (0%) 4 (10.3%)
aWald Chi-2 test using a generalized linear model. The P-value for the
main effect (difference between products) was adjusted on centers
Patients Gender/ age
(years)
BMI
(kg m
−2)
Volume
administered
(mL)
Relative variation
in creatinine
clearance (%)
Indications for MDCT
Iobitridol
#1 Female/11 18.3 74 -26 Bile-duct atresia with
secondary cirrhosis
complication
#2 Male/4 15.1 26 -32 Neck tumor
#3 Male/2 16.7 26 -39 Kawasaki disease
Iodixanol
#4 Female/12 15.6 88 -32 Liver transplantation
#5 Male/4 16 32 -40 Chronic osteomyelitis
#6 Female/7 17.2 50 -29 Cerebral tumor
#7 Female/12 14.3 50 -58 Cystic fibrosis
#8 Female/2 13.8 20 -28 Retroperitoneal tumor
#9 Male/1 16.6 24 -29 Pneumonia
#10 Female/16 22.9 70 -26 Pulmonary graft versus
host reaction
Table 4 Characteristics of
children with contrast
medium-induced nephropathy
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media, iodixanol (a nonionic, iso-osmolar dimer) and
iobitridol (a nonionic low-osmolar monomer), have consis-
tently been found adequately safe in adults, both in
intravenous administration to high-risk patients [26].
However, Chalmers and Jackson found that iodixanol was
less nephrotoxic than iohexol (another nonionic low-
osmolar monomer), when administered to patients with
renal impairment [27]. This superior safety of iodixanol
compared to iohexol was also suggested in the NEPHRIC
study [13].
In our study including children with normal renal
function, iobitridol 300, a low-osmolar contrast agent
(695 mOsm/Kg), appeared to be associated with a lower
CIN incidence rate (4.8%) compared to iodixanol 270
(10.6%), an iso-osmolar agent (290 mOsm/kg). To our
knowledge, this is the first study performed in children with
normal renal function; therefore, as there is no available
data regarding the CIN incidence on this kind of popula-
tion, no comparison can be made.
To evaluate whether iodixanol provides a general benefit
over other low-osmolar agents in patients with impaired
renal function, a number of prospective clinical studies
have been conducted recently. The results of these studies
showed that the overall benefit of iodixanol over other low-
osmolar agents cannot be demonstrated. Briguori and
colleagues [10] reported that CIN rates were not signifi-
cantly different when patients with chronic renal insuffi-
ciency were randomized to iodixanol or iobitridol for
angiography procedures. In the RECOVER study, iodixanol
was compared to the ionic dimer ioxaglate [11]. In this
latter study, a significant reduction in the CIN incidence
was shown with iodixanol, but only when the two
endpoints, serum creatinine increases≥0.5 mg/dL or 25%
from baseline, were combined. Another recent study, ICON,
[28] failed to demonstrate a benefit with iodixanol over
ioxaglate in patients with impaired renal function who
underwent cardiac angiography. Barrett and colleagues [12]
also reported low incidence of CIN in patients with chronic
kidney disease randomly assigned to receive iodixanol or
iopamidol for contrast-enhanced CT (2.6% versus 0%,
respectively, P=0.2). The CARE study [29], another and
larger study(414patients),alsofailedtodemonstrateabenefit
with iodixanol over iopamidol in renally impaired cardiac
angiography patients. Rates of CIN were comparable after
using the two agents (12.4% versus 9.4%, respectively, P=
0.44). In the ACTIVE trial (148 patients), Thomsen and
colleagues [30] concluded that the CIN incidence was
significantly higher after intravenous administration of
iodixanol 320 than iomeprol 400, with an overall rate of
CIN in all study groups of 3.4%. Kuhn and colleagues [14]
in the PREDICT study (248 patients) concluded that the
overall CIN rate was 5.2% with iodixanol 320 and iopamidol
370 in patients with both renal impairment and diabetes
mellitus who underwent CE-MDCT. Rudnick et al. in the
VALOR trial [31] including 299 patients showed that the
CIN incidence was 21.8% with iodixanol and 23.8% with
ioversol (P=0.78), and suggested that the nephrotoxicity
associated with iodixanol was not significantly different from
that observed with the low-osmolar contrast agent. In a
recent meta-analysis by Heinrich et al. [32], a reduction in
nephrotoxicity was seen only when iodixanol was compared
with iohexol, but no benefit was seen when this IOCM was
compared with other LOCM. The results of Alexopoulos et
al. [33] showed that no differences in contrast-induced acute
kidney injury incidence were apparent among patients
receiving nonionic iso-osmolar iodixanol and nonionic low-
osmolar contrast agents.
As described above, most of the published reports studied
adult patients with pre-existing renal insufficiency and the
criteria which identified cases of CIN were not uniform.
Also, the results of our study suggest that differences in
CIN incidence cannot be explained solely by differences in
contrast media osmolality [34]. The mechanism of contrast-
induced nephropathy is multifactorial and unclear. As
described in some studies, factors other than osmolality
(such as viscosity, temperature, hydrophilicity) may also
contribute to the toxic effect of contrast products [35–37],
and perhaps both osmolality and viscosity may also
contribute to nephrotoxicity.
The efficacy and safety of iobitridol have been assessed
recently in a double-blind, randomized study [38] and a
German postmarketing surveillance study involving more
than 160,000 patients [39], showing in both studies a
diagnostic value and a good safety profile of iobitridol.
Regarding the efficacy results in our study, the diagnostic
value of MDCT performed in children was shown. The
image quality rated “good” was high and similar in both
groups, with no statistically significant difference. Although
the incidence of patients rated “poor/moderate” was slightly
higher with iobitridol 300 (16.1%) than that observed with
iodixanol 270 (10.6%), this difference can be explained by
Table 5 Image quality and diagnostic efficacy assessments
Iobitridol 300
(n=62)
Iodixanol 270
(n=66)
P
a
Image quality
Poor/moderate 10 (16.1%) 7 (10.6%) 0.73
Good 52 (83.9%) 59 (89.4%)
Diagnostic efficacy
Impossible/difficult 6 (9.7%) 1 (1.5%) 0.58
Easy 56 (90.3%) 65 (98.5%)
aWald Chi-2 test using a generalized linear model. The P-value for the
main effect (difference between products) was adjusted on centres
1398 Pediatr Radiol (2011) 41:1393–1400patients with a high BMI and/or those not receiving a
sufficient dose. The diagnostic efficacy rated “easy” was
also similar in both groups, with no statistically significant
difference.
Finally, the similar and good safety profile of both
products was confirmed, and the low incidence of CIN
observed in our study suggests that prophylaxis is not
required in children when using iobitridol 300 and
iodixanol 270.
Conclusion
This trial suggests that, despite the greater iodine dose,
there was no statistically significant difference in the rate of
CIN between iobitridol 300 and iodixanol 270 in children
with normal renal function. The osmolality of the contrast
agent alone probably does not account for the differences in
the incidence of CIN. While previous reports have
suggested osmolality as a factor in the pathogenesis of
CIN at high osmolalities (>1,000 mOsm/kg), our results
suggest that osmolality in the range of 300 to approximate-
ly 700 is not nephrotoxic. Also, for contrast media within
this range of osmolality, other characteristics such as
viscosity or direct molecular toxicity may play a greater
role in the development of CIN. Future prospective clinical
trials comparing low and iso-osmolar, as well as low- and
high-viscosity CM in high-risk pediatric patients would be
of great interest to explore the role of osmolality and
viscosity in CIN.
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